EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian carcinoma after poly-ADP-ribose polymerase inhibitors progression: A real-world single-center experience

Naroa Amondarain Amenabar, Karmele Mujika Eizmendi, Laura Gabirondo Amenabar, Marina Crespo Cruz, Iker Muñagorri Quiles, Elide Gutiérrez San José, Malena García Álvarez, Iera Arrondo Arizmendi, Nerea Bengoa Fernández, Javier Martínez Amorena, Maddi Sánchez Urrestarazu, Larraitz Egaña Otaño und 1 weitere

Gynecologic Oncology Reports · 2026-10 · 67 · 102198

DOI: 10.1016/j.gore.2026.102198 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gynecologic Oncology Reports, 2026-10. Verfasst von Naroa Amondarain Amenabar und 12 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Hospital Universitario Donostia, Donostia, Spain. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PharmaMar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Platinum-based chemotherapy remains the cornerstone of treatment for recurrent ovarian cancer; however, optimal treatment sequencing after progression on PARP inhibitors (PARPi) remains uncertain, particularly in patients with partially platinum-sensitive disease. Objective: to evaluate the efficacy, safety, and subsequent treatment patterns associated with trabectedin plus pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer who had progressed after prior PARPi exposure.

Methods

This retrospective, single-center real-world study included patients with recurrent ovarian cancer, a platinum-free interval of 6-12 months, and progression after prior PARPi exposure.

Results

Twenty-five patients were included. The median age was 68.8 years, median platinum-free interval was 7.0 months, and patients had received a median of three prior lines of therapy. The objective response rate (ORR) was 24.0% and disease control rate (DCR) was 64.0%. Median progression-free survival (PFS) and overall survival (OS) were 7.9 and 19.9 months, respectively. Following progression on trabectedin plus PLD, 76.0% of patients received subsequent platinum-based chemotherapy, with an ORR of 33.3% among those receiving immediate platinum rechallenge. Toxicities were predominantly hematological, with no unexpected safety signals.

Conclusions

In this real-world, heavily pretreated post-PARPi population with partially platinum-sensitive disease, trabectedin plus PLD demonstrated clinically meaningful activity with an acceptable safety profile. In a setting where available evidence remains limited and heterogeneous, these findings provide additional clinically relevant data in a well-defined subgroup and support its use as a feasible treatment option in selected patients. Prospective studies are warranted to further define optimal treatment sequencing after PARPi exposure.

Schlagwörter

Stichwörter der Autor:innen

PARP inhibitorsPlatinum sensitivityRecurrent ovarian cancerTrabectedin-pegylated liposomal doxorubicin

Autor:innen und Institutionen

  • Medical Oncology Department, Hospital Universitario Donostia, Donostia, Spain.
  • Medical Oncology Department, University College London Hospitals NHS Foundation Trust, London, UK.

Förderung

  • PharmaMar

Zitieren

APA

Amondarain Amenabar, N., Mujika Eizmendi, K., Gabirondo Amenabar, L., Crespo Cruz, M., Muñagorri Quiles, I., Gutiérrez San José, E., García Álvarez, M., Arrondo Arizmendi, I., Bengoa Fernández, N., Martínez Amorena, J., Sánchez Urrestarazu, M., Egaña Otaño, L., & Churruca Galaz, C. (2026). Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian carcinoma after poly-ADP-ribose polymerase inhibitors progression: A real-world single-center experience. Gynecologic Oncology Reports, 67, 102198. https://doi.org/10.1016/j.gore.2026.102198

Vancouver

Amondarain Amenabar N, Mujika Eizmendi K, Gabirondo Amenabar L, Crespo Cruz M, Muñagorri Quiles I, Gutiérrez San José E, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian carcinoma after poly-ADP-ribose polymerase inhibitors progression: A real-world single-center experience. Gynecologic Oncology Reports. 2026;67:102198. doi:10.1016/j.gore.2026.102198

BibTeX
@article{AmondarainAmenabar2026,
  author = {Amondarain Amenabar, Naroa and Mujika Eizmendi, Karmele and Gabirondo Amenabar, Laura and Crespo Cruz, Marina and Muñagorri Quiles, Iker and Gutiérrez San José, Elide and García Álvarez, Malena and Arrondo Arizmendi, Iera and Bengoa Fernández, Nerea and Martínez Amorena, Javier and Sánchez Urrestarazu, Maddi and Egaña Otaño, Larraitz and Churruca Galaz, Cristina},
  title = {Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian carcinoma after poly-ADP-ribose polymerase inhibitors progression: A real-world single-center experience},
  journal = {Gynecologic Oncology Reports},
  year = {2026},
  volume = {67},
  pages = {102198},
  doi = {10.1016/j.gore.2026.102198}
}
Kostenlos starten →